Evidence map›Paper›PMID 39398932›Full record

ArticleInternational cancer conference journal2024

Ileal perforation at the site of peritoneal metastasis with intestinal infiltration by dual EGFR-VEGF pathway inhibition in an EGFR-mutant non-small cell lung cancer patient.

Tomomi Sanomachi, Tatsuya Yoshida, Ryoko Inaba Higashiyama, Yaya Satozono, Shiho Matsunaga, Yukihide Kanemitsu, Yuichiro Ohe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tomomi SanomachiDepartment of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045 Japan.
Tatsuya YoshidaDepartment of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045 Japan.
Ryoko Inaba HigashiyamaDepartment of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045 Japan.
Yaya SatozonoDepartment of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045 Japan.
Shiho MatsunagaDepartment of Colorectal Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045 Japan.
Yukihide KanemitsuDepartment of Colorectal Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045 Japan.
Yuichiro OheDepartment of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal (GI) perforation including ileal perforation is a rare complication of antivascular endothelial growth factor (anti-VEGF) therapy. Risk factors of GI perforation have not been fully understood. This report highlights the case of a patient who experienced GI perforation at the site of peritoneal metastasis with intestinal infiltration immediately after treatment with dual epidermal growth factor receptor (EGFR)-VEGF pathway inhibition agents for EGFR-mutant non-small cell lung cancer (NSCLC). The administration of dual EGFR-VEGF pathway inhibition agents in EGFR mutant NSCLC patients appears to elevate the risk of GI perforation. This report provides insights into the association between EGFR mutant NSCLC and the susceptibility to GI perforation following treatment with dual EGFR-VEGF pathway inhibition agents.

Indexed as

Drug therapyEpidermal growth factor receptorNon-small cell lung cancerVascular endothelial growth factor receptor

Identifiers

PMID39398932
PMCPMC11464858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.